BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32961022)

  • 21. Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison.
    Nepstad I; Hatfield KJ; Aasebø E; Hernandez-Valladares M; Brenner AK; Bartaula-Brevik S; Berven F; Selheim F; Skavland J; Gjertsen BT; Reikvam H; Bruserud Ø
    Expert Opin Ther Targets; 2018 Jul; 22(7):639-653. PubMed ID: 29889583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
    Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
    Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.
    Xu G; Zhang W; Bertram P; Zheng XF; McLeod H
    Int J Oncol; 2004 Apr; 24(4):893-900. PubMed ID: 15010827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
    Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I
    Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
    Han S; Khuri FR; Roman J
    Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.
    Rao VK; Webster S; Dalm VASH; Šedivá A; van Hagen PM; Holland S; Rosenzweig SD; Christ AD; Sloth B; Cabanski M; Joshi AD; de Buck S; Doucet J; Guerini D; Kalis C; Pylvaenaeinen I; Soldermann N; Kashyap A; Uzel G; Lenardo MJ; Patel DD; Lucas CL; Burkhart C
    Blood; 2017 Nov; 130(21):2307-2316. PubMed ID: 28972011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dominant Splice Site Mutations in PIK3R1 Cause Hyper IgM Syndrome, Lymphadenopathy and Short Stature.
    Petrovski S; Parrott RE; Roberts JL; Huang H; Yang J; Gorentla B; Mousallem T; Wang E; Armstrong M; McHale D; MacIver NJ; Goldstein DB; Zhong XP; Buckley RH
    J Clin Immunol; 2016 Jul; 36(5):462-71. PubMed ID: 27076228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Profile of Toll-like Receptor 2 (TLR2), TLR4 and Their Cytosolic Downstream Signaling Pathway in Common Variable Immunodeficiency (CVID) Patients.
    Sharifi L; Aghamohammadi A; Rezaei N; Yazdani R; Mahmoudi M; Amiri MM; Masoumi F; Bokaie S; Tavasolian P; Sanaei R; Moshiri M; Tavakolinia N; Alinia T; Azizi G; Mirshafiey A
    Iran J Allergy Asthma Immunol; 2018 Apr; 17(2):188-200. PubMed ID: 29757592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
    Yazdani R; Hamidi Z; Babaha F; Azizi G; Fekrvand S; Abolhassani H; Aghamohammadi A
    Endocr Metab Immune Disord Drug Targets; 2019; 19(7):941-958. PubMed ID: 30799802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.
    Jamee M; Moniri S; Zaki-Dizaji M; Olbrich P; Yazdani R; Jadidi-Niaragh F; Aghamahdi F; Abolhassani H; Condliffe AM; Aghamohammadi A; Azizi G
    Clin Rev Allergy Immunol; 2020 Dec; 59(3):323-333. PubMed ID: 31111319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines.
    Riquelme I; Tapia O; Espinoza JA; Leal P; Buchegger K; Sandoval A; Bizama C; Araya JC; Peek RM; Roa JC
    Pathol Oncol Res; 2016 Oct; 22(4):797-805. PubMed ID: 27156070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Immune TOR-opathies," a Novel Disease Entity in Clinical Immunology.
    Jung S; Gámez-Díaz L; Proietti M; Grimbacher B
    Front Immunol; 2018; 9():966. PubMed ID: 29867948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of the phosphoinositide 3-kinase-Akt-mammalian target of the rapamycin signaling pathway in long-term potentiation and trace fear conditioning memory in rat medial prefrontal cortex.
    Sui L; Wang J; Li BM
    Learn Mem; 2008 Oct; 15(10):762-76. PubMed ID: 18832563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IL-21 and anti-CD40 restore Bcl-2 family protein imbalance in vitro in low-survival CD27
    López-Gómez A; Clemente A; Cunill V; Pons J; Ferrer JM
    Cell Death Dis; 2018 Nov; 9(12):1156. PubMed ID: 30464201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phenotypic and Functional Comparison of Class Switch Recombination Deficiencies with a Subgroup of Common Variable Immunodeficiencies.
    Aan de Kerk DJ; Jansen MH; Jolles S; Warnatz K; Seneviratne SL; Ten Berge IJ; van Leeuwen EM; Kuijpers TW
    J Clin Immunol; 2016 Oct; 36(7):656-66. PubMed ID: 27484504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
    Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
    Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
    Han L; Qiu P; Zeng Z; Jorgensen JL; Mak DH; Burks JK; Schober W; McQueen TJ; Cortes J; Tanner SD; Roboz GJ; Kantarjian HM; Kornblau SM; Guzman ML; Andreeff M; Konopleva M
    Cytometry A; 2015 Apr; 87(4):346-56. PubMed ID: 25598437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of the Interleukin-21 Pathway with Interleukin-4 Distinguishes Common Variable Immunodeficiency Patients with More Non-infectious Clinical Complications.
    Desjardins M; Béland M; Dembele M; Lejtenyi D; Drolet JP; Lemire M; Tsoukas C; Ben-Shoshan M; Noya FJD; Alizadehfar R; McCusker CT; Mazer BD
    J Clin Immunol; 2018 Jan; 38(1):45-55. PubMed ID: 29103189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
    Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD
    Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.